Lotilaner
Ectoparasiticide — SENSORY ORGANS
Also known as: credelio
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Lotilaner is an onp drug in the Ectoparasiticide class catalogued in DrugCentral. It was first approved by the FDA in 2023. DrugCentral lists 1 molecular target, including GABA-A receptor. Recorded indications include Demodex blepharitis.
- Approval status: onp (first approved 2023 by the FDA).
- Drug class: Ectoparasiticide.
- Molecular targets: GABA-A receptor (1 listed in DrugCentral).
- Indications: Demodex blepharitis.
- ATC code: S01AX25 (Other antiinfectives).
- Molecular formula: C20H14Cl3F6N3O3S; molecular weight 596.75 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Demodex blepharitis
Mechanism & targets
| Established pharmacologic class | Ectoparasiticide |
|---|
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| GABA-A receptor | — | inhibitor | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2023-07-24 | FDA | — | TARSUS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
S01AX25 | SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Other antiinfectives |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Eye irritation | 1012.1 |
| Instillation site irritation | 601.7 |
| Ocular hyperaemia | 547.9 |
| Eye pruritus | 343.5 |
| Eye pain | 333.1 |
| Vision blurred | 323.9 |
| Product prescribing issue | 250.7 |
| Lacrimation increased | 212.8 |
| Therapy interrupted | 201.4 |
| Wrong technique in product usage process | 185.9 |
| Swelling of eyelid | 185.0 |
| Eye discharge | 174.8 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Lotilaner is on its molecule page.
| Molecular formula | C20H14Cl3F6N3O3S |
|---|---|
| Molecular weight | 596.75 g/mol |
| CAS number | 1369852-71-0 |
| InChIKey | HDKWFBCPLKNOCK-SFHVURJKSA-N |
| PubChem CID | 76959255 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Lotilaner used for?
DrugCentral lists the following indications for Lotilaner: Demodex blepharitis.
How does Lotilaner work?
Its molecular targets in DrugCentral include GABA-A receptor (inhibitor).
When was Lotilaner first approved?
Lotilaner was first approved by the FDA in 2023.
What drug class does Lotilaner belong to?
Lotilaner is in the Ectoparasiticide class.
What is the chemical formula of Lotilaner?
Lotilaner has the molecular formula C20H14Cl3F6N3O3S and a molecular weight of 596.75 g/mol.
Browse: all drugs starting with L · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5567 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3707310 — compound record and bioactivity
- PubChem CID 76959255 — chemical identifiers
- FDA UNII HEH4938D7K — substance identity
- DailyMed: FDA labels for Lotilaner — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.